Traws Pharma, Inc. Payments to Acquire Marketable Securities
Traws Pharma, Inc. (TRAW) reported Payments to Acquire Marketable Securities of $39.99 million for the 12-month period ending 2013-12-31, per its 10-K filed 2015-03-30.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2015-03-30
- Traws Pharma, Inc. payments to acquire marketable securities for the quarter ending 2013-12-31 was $0.00.
- Traws Pharma, Inc. payments to acquire marketable securities for fiscal 2013 was $39.99M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-30 | $39.99M 10-K · filed 2015-03-30 | |
| 2013-09-30 | $39.99M 10-Q · filed 2013-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |